Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.45 |
| ▸ | NOS2 | P35228 | 3/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2152875 | 1.00 | NOS3 (0.45) | NOS3NOS1NOS2PARP10PPARG | |
| SCHEMBL29400473 | 0.85 | SLC7A5 (0.58) | NOS3NOS1NOS2PPARGPPARA | |
| SCHEMBL1250588 | 0.85 | SLC7A5 (0.58) | NOS3NOS1NOS2PPARGPPARA | |
| SCHEMBL43302 | 0.85 | SLC7A5 (0.58) | NOS3NOS1NOS2PPARGPPARA | |
| SCHEMBL43301 | 0.85 | SLC7A5 (0.58) | NOS3NOS1NOS2PPARGPPARA | |
| SCHEMBL25413235 | 0.80 | TAAR1 (0.42) | NOS3NOS1NOS2PPARGPPARA | |
| SCHEMBL16271273 | 0.80 | POLB (0.43) | NOS3NOS1NOS2PARP10PPARG | |
| SCHEMBL30523454 | 0.80 | POLB (0.43) | NOS3NOS1NOS2PARP10PPARG | |
| SCHEMBL25410822 | 0.80 | TAAR1 (0.42) | NOS3NOS1NOS2PPARGPPARA | |
| SCHEMBL2152877 | 0.80 | POLB (0.43) | NOS3NOS1NOS2PARP10PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833789-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSM IP ASSETS BV (NL) | 2011-07-06 | — | — | EP | disclosed |
| CN-101090886-B | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acids | DSM IP ASSETS BV | 2011-05-18 | — | — | CN | disclosed |
| US-7732621-B2 | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid | DSM IP ASSETS B.V. (NL) | 2010-06-08 | — | — | US | disclosed |
| EP-2069518-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE PHENYLALANINE COMPOUNDS FROM CINNAMIC ACID DERIVATIVES EMPLOYING A PHENYLALANINE AMMONIA LYASE DERIVED FROM IDIOMARINA LOIHIENSIS | DSM IP ASSETS BV (NL) | 2010-02-03 | — | — | EP | disclosed |
| EP-2069518-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE PHENYLALANINE COMPOUNDS FROM CINNAMIC ACID DERIVATIVES EMPLOYING A PHENYLALANINE AMMONIA LYASE DERIVED FROM IDIOMARINA LOIHIENSIS | DSMIP Assets B.V. (NL) | 2009-06-17 | — | — | EP | disclosed |
| US-20090043112-A1 | Process for the Preparation of Enantiomerically Enriched Indoline-2-Carboxylic Acid | DSM IP ASSETS B.V. (NL) | 2009-02-12 | — | — | US | disclosed |
| WO-2008031578-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE PHENYLALANINE COMPOUNDS FROM CINNAMIC ACID DERIVATIVES EMPLOYING A PHENYLALANINE AMMONIA LYASE DERIVED FROM IDIOMARINA LOIHIENSIS | DSM IP ASSETS B.V. (NL) | 2008-03-20 | — | — | WO | disclosed |
| CN-101090886-A | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acids | DSM IP ASSETS BV (NL) | 2007-12-19 | — | — | CN | disclosed |
| EP-1833789-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSMIP Assets B.V. (NL) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069799-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSM IP ASSETS B.V. (NL) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676838-A1 | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid | DSM IP Assets B.V. (NL) | 2006-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043112-A1 | Process for the Preparation of Enantiomerically Enriched Indoline-2-Carboxylic Acid | IDO2, IDO1, KYNU | NOS3 3090/4885NOS1 2787/4885NOS2 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.